ArticleStem cell research & therapy2025
ROS-responsive 3D biological scaffold delivers hypoxia-primed extracellular vesicles for targeted modulation of neuroinflammation in intracerebral hemorrhage.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A review of recent advances in exosome-mediated drug delivery for regenerative therapy and immunomodulation.Biomedical engineering online · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEmerging evidence suggests that paracrine mechanisms may underlie the therapeutic effects of human umbilical cord mesenchymal stem cell-derived extracellular vesicles (EVs) (hUCMSC-exos) in mitigating neuroinflammation following intracerebral hemorrhage (ICH). Hypoxic preconditioning enhances the paracrine efficacy of hUCMSC-exos. Building on prior studies [1, 2], we developed a ROS-responsive three-dimensional (3D) biological scaffold encapsulating hypoxia-primed EVs (Hypo-Exos) for sustained release under reactive oxygen species (ROS)-rich conditions.
methodsThe 3D biological scaffold was fabricated via a thermoresponsive crosslinking strategy using gelatin methacrylate (GelMA), silk fibroin, and brain-derived decellularized extracellular matrix (dECM), functionalized with phenylboronic acid (PBA)-modified polyvinyl alcohol (PVA). Hypo-Exos, enriched with miR-146b via hypoxia-inducible factor-1α (HIF-1α) activation, were incorporated into the scaffold using advanced 3D bioprinting. Dual-luciferase reporter assays validated miR-146b targeting of the 3'UTR of COP1 (an E3 ubiquitin ligase). In a rat ICH model, the scaffold was implanted in situ. Neurological function, angiogenesis, neuroinflammation, and synaptic plasticity were evaluated at days 1, 4, 7, and 14.
resultsThe 3D biological scaffold enabled sustained delivery of Hypo-Exos, shifting microglial polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, thereby attenuating neuroinflammation and neuronal damage. Mechanistically, miR-146b suppressed COP1 expression via post-transcriptional silencing, thereby attenuating NF-κB p65 signaling and downregulating pro-inflammatory cytokines.
conclusionThe ROS-responsive 3D biological scaffold -mediated delivery of Hypo-Exos modulates neuroinflammation through ubiquitination pathways, stabilizes the early-phase ICH microenvironment, and improves functional recovery. This platform represents a promising therapeutic strategy for ICH, offering dual advantages as a drug delivery system and a regenerative therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.